二级市场方面，截至发稿，中国中冶A股开盘下挫，逼近跌停，港股下跌超20% | Ａ股 | | | | 港股 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 3.06元 -0.33 -9.73% | | | | | | | | | 交易中 12-09 10:13:00 北京时间 | | | | | | | | | 今开 | 3.23 | | 最高 | 3.23 | | 成交量 | 500.18万手 | | 昨收 | 3.39 | | 最低 | 3.05 | | 成交额 | 15.44亿 | | 换手率 | 2.80% | | 市盈(TTM) | 16.32 | | 总市值 | 634.14亿 | | 分时 | 王日 | 日K | 周K | 月K | 季K | 年K | 亜多い | | 3.23 | | | | | | | -4.72% | | 14 | | | | | | | -7.38% | | | | | | | | | -10.03% | 12月8日晚间，中国中冶（SH601618，股价3.39元，市值702.53亿元）发布公告称，拟将 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、已披露的拟对外出售资产暨关联交易概述 芯联集成电路制造股份有限公司（以下简称"公司"、"芯联集成"）在芯片实验室检测领域深耕数年，在 硬件设施、实验设备、软件、技术、资质、经验和人员等方面有了丰富的积累。为了更好的服务客户， 扩大检测收入，优化产品结构，公司控股子公司芯联先锋集成电路制造（绍兴）有限公司（以下简 称"芯联先锋"）与临港新片区基金设立合资公司上海芯港联测半导体有限责任公司（以下简称"芯港联 测"、"受让方"）。合资公司注册资本人民币40,000.00万元，芯联先锋使用自有资金出资人民币 20,000.00万元，占注册资本总额50.00%。为快速推动项目的建设，实现合资公司业务的独立开展，公 司及公司子公司将持有的检测业务设备、专利及非专利型专有技术转让给芯港联测。公司于2025年9月 12日、2025年9月29日分别召开第二届董事会第八次会议和2025年第二次临时股东大会，审议通过了 《关于拟对外出售资产暨关联交易的议案》。具体内容详见公司于2025年9月1 ...

作为央企内部资源整合，这笔交易买方均为中国中冶的控股股东中国五矿集团有限公司(以下简称中国五矿)及其关联方。 二级市场方面，截至发稿，中国中冶A股开盘下挫，逼近跌停，港股下跌超20% | Ａ股 | | | | 港股 | | | | --- | --- | --- | --- | --- | --- | --- | | 3.06元 -0.33 -9.73% | | | | | | | | 交易中 12-09 10:13:00 北京时间 | | | | | | | | 今开 | 3.23 | 最高 | 3.23 | | 成交量 | 500.18万手 | | 昨收 | 3.39 | 最低 | 3.05 | | 成交额 | 15.44亿 | | 换手率 | 2.80% | 市盈(TTM) | 16.32 | | 总市值 | 634.14亿 | | 分时 日K | 王日 | 周K | 月K | 塾K | 年K | 亜多い | | 3.23 | | | | | | -4.72% | | 14 | | | | | | -7.38% | | | | | | | | -10.03% | | A股 | | | | | 港股 | ...

截至12月8日收盘，中国中冶股价为3.39元，市值为667亿元。 12月8日晚，中国中冶公告(601618.SH)称，公司拟将所持有的中冶置业100%股权及对中冶置业的标的 债权，有色院、中冶铜锌、瑞木管理100%股权，中冶金吉67.02%股权，以及华冶杜达100%股权出售给 五矿地产控股和中国五矿，交易价格为606.76亿元。本次交易构成关联交易，不构成重大资产重组，已 达到股东会审议标准，需提交股东会审议批准。 0:00 ...

远东发展宣布，其全资附属公司已与The Generation Essentials Group(纽交所：TGE)签订买卖协议，有条 件同意以1亿澳元（约合5.15亿港元）的总代价，出售其在澳大利亚珀斯丽思卡尔顿酒店相关营运及物 业公司的股权，并承让销售贷款。公司董事认为，此次交易旨在变现酒店价值、实现资本循环投资、提 升集团流动性并优化其净资产负债比率，与集团释放酒店组合利润和出售非核心资产的战略相符。 （文章来源：证券时报网） ...

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

目标集团包括营运公司、物业公司及RC营运公司。于本公告日期，营运公司为一间于澳洲注册成立的 公司及FEC Hotel的全资附属公司。营运公司主要从事投资控股。于本公告日期，物业公司为一间于澳 洲注册成立的公司及FEC Holdings的全资附属公司。物业公司主要从事物业投资。于本公告日期，RC 营运公司为一间于澳洲注册成立的公司及本公司的全资附属公司。RC营运公司主要从事酒店营运。 智通财经APP讯，远东发展(00035)发布公告，于2025年12月8日，本公司的全资附属公司FEC Holdings 及FEC Hotel作为卖方与买方The Generation Essentials Group(纽交所：TGE)订立买卖协议，卖方有条件 同意出售而买方有条件同意购买销售股份(营运公司RC Perth Operations Pty Ltd及物业公司Perth FEC Pty Ltd各自于完成日期的50%已发行股份)及承让销售贷款，总代价为1亿澳元(相当于约港币5.15亿元)。 据悉，该酒店位于1 Barrack St, Perth WA 6000, Australia的珀斯丽思卡尔顿酒店。 董事认为，交易将会( ...

Core Viewpoint - Stonepeak has emerged as a major competitor in the acquisition of BP's Castrol lubricants business, with negotiations centered around a bid valuing the business at over $8 billion [1] Group 1: Acquisition Details - BP put the Castrol lubricants business up for sale in February, with analysts initially estimating a potential sale price exceeding $10 billion [1] - The sale is part of BP's strategy to raise $20 billion through asset disposals by 2027, with the Castrol sale expected to contribute significantly to this target [1] - Initial bidders were deterred by the high price, but a deal at over $8 billion aligns with BP's current expectations [1] Group 2: Transaction Structure - Stonepeak may pursue a transaction structure similar to its recent acquisition of a majority stake in Phillips 66's subsidiary, where Phillips 66 retained a 35% minority stake [1] Group 3: Other Asset Sales - BP is also seeking buyers for a 50% stake in its Lightsource solar business, with expectations to raise $4 billion through asset disposals this year [1]

Group 1 - ST TaiZhong announced the sale of its wholly-owned subsidiary Shanxi TaiZhong Coking Equipment Co., Ltd. to its controlling shareholder TaiZhong Group for approximately 618 million yuan to optimize asset structure and improve liquidity and debt repayment capability [1] - The transaction does not constitute a major asset restructuring as defined by the regulations on major asset restructuring of listed companies [1] - For the first half of 2025, ST TaiZhong's revenue composition is 77.88% from heavy equipment products and 22.12% from engineering machinery products [1] Group 2 - As of the report date, ST TaiZhong's market capitalization is 7.8 billion yuan [2]

Core Viewpoint - ST TaiZhong (600169) announced the sale of its wholly-owned subsidiary Shanxi TaiZhong Coking Equipment Co., Ltd. to its controlling shareholder Taiyuan Heavy Machinery Group Co., Ltd. for a price of 618 million yuan, aiming to optimize asset structure and enhance liquidity and debt repayment capability [1] Group 1 - The company intends to sell 100% equity of Shanxi TaiZhong Coking Equipment Co., Ltd. [1] - The sale is conducted through a non-public agreement [1] - The transfer price for the subsidiary is set at 618 million yuan [1]